14
Participants
Start Date
May 31, 2016
Primary Completion Date
October 19, 2017
Study Completion Date
October 19, 2017
Testosterone
Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
Progesterone
Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
Placebo
Subjects will receive placebo transdermal gel and placebo (lactose) capsules
Ibutilide
Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
Indiana University, Indianapolis
American Heart Association
OTHER
Purdue University
OTHER
Indiana University
OTHER